The FDA has recently approved Wegovy, an injectable semaglutide medication, for use as a heart disease prevention medication. This groundbreaking decision now allows Wegovy to be used to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who are overweight or obese. This marks the first time a weight-loss medication has been approved for this additional indication.
However, it is important to note that Wegovy should not be taken with other semaglutide or GLP-1 products. The approval of Wegovy comes after a large, randomized, double-blind trial showed significant results supporting its efficacy in preventing cardiovascular events in those with obesity and overweight.
Experts view this approval as a major advance for public health and a landmark decision in medical therapy for obesity. The approval of Wegovy is also expected to combat bias and stigma surrounding weight-loss medications, with experts predicting that many similar medications will enter the market in the future.
Patients are encouraged to discuss with their healthcare provider about the potential benefits and side effects of Wegovy before starting the medication. This approval highlights the importance of innovative medications in addressing complex health issues and paves the way for further advancements in the field of obesity treatment.
“Travel aficionado. Incurable bacon specialist. Tv evangelist. Wannabe internet enthusiast. Typical creator.”